Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

NIH 8OTHER 5INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 10Genitourinary 3Other hematologic neoplasm 2Plasma cell 1Gastrointestinal 1Dermatologic 1

Conditions

Lymphoma 2Hematologic Neoplasms 2

Interventions

Azacitidine 160venetoclax 149Cytarabine 123Rituximab 94fludarabine 76Cyclophosphamide 70Imatinib Mesylate 59nilotinib 55ibrutinib 54Dasatinib 48obinutuzumab 47Bendamustine Hydrochloride 43Decitabine 39Daunorubicin 38idelalisib 31acalabrutinib 31Dexamethasone 29Chlorambucil 29Idarubicin 26gilteritinib 24Lenalidomide 23bosutinib 21asciminib 21ofatumumab 20blinatumomab 19pirtobrutinib 18fludarabine phosphate 18Vincristine 18zanubrutinib 16ublituximab 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × romidepsin × Other hematologic neoplasm × Clear all
NCT01324310 2019-11-25

Influence of Ketoconazole on the Pharmacokinetics of Romidepsin in Patients With Advanced Cancer

Celgene

Phase 1 Completed
15 enrolled 21 charts
LymphoidOther hematologic neoplasm

Lymphoma, Hematologic Neoplasms

NCT01324323 2019-11-25

Influence of Rifampin on the Pharmacokinetics of Romidepsin in Patients With Advanced Cancer

Celgene

Phase 1 Completed
14 enrolled 21 charts
LymphoidOther hematologic neoplasm

Lymphoma, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡